Metformin for Longevity: Should Healthy Adults Take It?

Should healthy adults take metformin for longevity? For now, the cautious answer is usually no unless there is a clear metabolic reason and medical supervision. Metformin is a proven diabetes drug with credible longevity biology, but the case for metabolically healthy adults is still unproven.

This guide reviews the 2026 evidence on metformin for longevity: plausible benefits, TAME trial status, diabetes vs healthy-adult use, side effects, muscle and B12 concerns, and when a doctor-led biomarker review makes more sense than self-medication.

Updated on June 21, 2026. This refresh incorporates the official TAME status, the DPP/DPPOS follow-up published in JAMA on June 15, 2026, the MET-PREVENT trial in The Lancet Healthy Longevity, the 2025 critical review on observational bias, data on metformin and exercise, and official safety guidance on eGFR, iodinated contrast and vitamin B12.

TL;DR: metformin longevity benefits and safety in 2026

Medical caveat: metformin makes strong medical sense in type 2 diabetes, prediabetes, and insulin resistance. As a longevity drug for metabolically healthy people, the evidence still does not justify self-medication.

• Most plausible benefit: better glucose and insulin control when metabolic risk is present.
• Main uncertainty: no completed trial proves longer healthspan in healthy adults.
• Main safety checks: kidney function, vitamin B12, GI tolerance, medication interactions, and exercise goals.
• Best next step: review HbA1c, fasting insulin, body composition, muscle status, and lifestyle fundamentals before discussing a prescription.

Key evidence to know: the metformin aging rationale explains why metformin is being tested for aging biology, while the MILES transcriptomic study, the MASTERS trial and the MET-PREVENT trial are reminders that biomarkers do not always translate into better strength or function.

Situation	What we know	Prudent decision
Type 2 diabetes or prediabetes	Proven metabolic benefit; lowers diabetes progression in higher-risk profiles	Discuss with a physician and biomarkers
Normal metabolism and strength training	No proven clinical longevity benefit; may blunt muscle adaptations	Prioritize strength, protein, sleep, and follow-up
Frailty or sarcopenia	MET-PREVENT 2025 did not improve walking speed and was poorly tolerated	Do not use it as a sarcopenia treatment
Anti-aging interest without medical indication	TAME has no published efficacy results yet	Wait for data; track HbA1c, insulin, B12, and kidney function

What changed in 2025-2026

The online conversation around metformin and longevity still splits into two camps: headlines presenting it as a cheap pill to live longer, and reviews urging more caution. The useful answer sits between them. The biology remains interesting, but the most reasonable clinical candidate is not the healthy adult looking for a shortcut; it is the person with measurable metabolic risk.

• DPP/DPPOS added the most useful clinical-longevity signal: in JAMA, June 2026, 1,173 adults with prediabetes followed for 21 years had lower multimorbidity risk if originally assigned to intensive lifestyle intervention; metformin was not significantly different from placebo for that outcome.
• TAME still has no efficacy results: AFAR describes it as a prepared multicenter design, with more than 3,000 adults aged 65-79 planned, but no published results proving delayed aging.
• MET-PREVENT cooled the sarcopenia idea: in older adults with probable sarcopenia and frailty, 4 months of metformin did not improve strength, walking speed or quality of life, and tolerability was worse.
• Recent reviews separate mechanism from clinic: a critical 2025 review keeps AMPK, mTOR, autophagy and inflammation as plausible pathways, but that does not equal a recommendation for healthy adults without insulin resistance.
• The practical filter is narrower: high HbA1c, high fasting insulin, visceral fat or prediabetes make a medical discussion more plausible; normal metabolism plus a muscle or performance goal shifts the priority elsewhere.

To make this decision data-led, the Optimization program, diagnostics and treatments, our guide to longevity biomarkers, and an initial medical assessment help review glucose, insulin, body composition, muscle status, nutrition and follow-up before discussing medication.

Metformin dosage for longevity: why there is no validated protocol

One of the most common searches is "metformin dosage for longevity". The responsible answer is less convenient than a number: there is no validated anti-aging dose. There are approved clinical doses for diabetes and physician-led metabolic contexts, and there are doses used in trials. That is not the same as a protocol for healthy adults.

Context	Dose used or proposed	Correct interpretation
MILES	1,700 mg/day for 6 weeks in older adults with impaired glucose tolerance.	Small biomarker and gene-expression study; it did not measure clinical longevity.
TAME	Proposed design using 1,500 mg/day for 6 years in adults aged 65-79.	No published efficacy results yet; it does not prove that this dose delays aging.
MET-PREVENT	500 mg three times daily for 4 months in older adults with probable sarcopenia and frailty.	It did not improve physical performance and tolerability was worse, so it does not support use for muscle or frailty.
Clinical metabolic use	Dose depends on indication, tolerance, kidney function and physician judgment.	The first question is not "how much", but whether there is a medical indication and a monitoring plan.

The confusion starts when a research dose is copied as if it were a longevity prescription. In precision medicine, the decision begins earlier: HbA1c, glucose, insulin, visceral fat, body composition, training, eGFR, B12, alcohol, medications and the real goal. Someone with prediabetes and visceral fat does not have the same benefit-risk balance as a lean, active person with healthy glucose control.

Monitoring and temporary pauses: kidney, contrast, B12 and surgery

If metformin is used for a medical indication, safety is not optional. DailyMed/NIH prescribing information and diabetes guidelines put four checks at the center: kidney function, iodinated contrast procedures, vitamin B12 and temporary pauses during acute illness or procedures.

Practical question	Safety criterion	Why it matters
Can it be started with low eGFR?	Do not use if eGFR is <30 mL/min/1.73 m²; initiation is not recommended between 30-45.	Accumulation and lactic acidosis risk increase as kidney function falls.
What if eGFR falls?	Reassess benefit-risk if it falls below 45; discontinue if it falls below 30.	Safety matters more than any longevity hypothesis.
Should it be paused for contrast imaging?	Stop at or before iodinated contrast if eGFR is 30-60, liver disease, alcoholism, heart failure or intra-arterial contrast; recheck eGFR after 48 h.	Contrast can precipitate acute kidney injury in higher-risk profiles.
When should B12 be monitored?	Annual blood counts and B12 every 2-3 years during long-term use; sooner with anemia, neuropathy, restrictive diets or older age.	Metformin can lower B12 and confuse fatigue, neuropathy or cognitive symptoms.
What about surgery or acute illness?	Discuss temporary pauses during surgery, prolonged fasting, dehydration, sepsis, hypoxia or restricted intake.	These scenarios increase renal, hemodynamic or acidosis risk.

This is what separates a medical conversation from a trend: before discussing dose, you need to know whether there is an indication, whether kidney function allows it, whether B12 is being tracked and whether muscle is protected. In longevity medicine, a drug that improves one marker while worsening function or recovery is not a win.

Decision by phenotype: when the balance changes

Metformin should not be decided by chronological age or anti-aging enthusiasm. Metabolic and functional context matter more.

Profile	Clinical read	Priority before discussing a prescription
Prediabetes, visceral fat or high insulin	There may be a reasonable metabolic indication if a physician confirms it.	Weight, waist, HbA1c, insulin, nutrition, strength and follow-up.
Healthy adult who strength-trains	Longevity benefit is unproven and exercise adaptations may be blunted.	Strength, protein, sleep, VO₂max, ApoB, glucose and recovery.
Older adult with frailty or sarcopenia	MET-PREVENT does not support metformin as a functional geroprotector.	Supervised strength, protein, vitamin D if deficient, falls risk and medication review.
Low eGFR, liver disease, high alcohol intake or upcoming contrast imaging	Safety may outweigh any anti-aging hypothesis.	Renal/liver function, pause plan and medication review.
Strict vegan diet, chronic PPI use, anemia or neuropathy	B12 deserves special attention before and during treatment.	B12, blood count, MMA/homocysteine if unclear and neurological symptoms.

What metformin is and why it is studied for longevity

Metformin belongs to the biguanide class of drugs. Its origin traces back to Galega officinalis (French lilac), a plant used for centuries in Europe for symptoms we now recognize as diabetes. It was approved in the UK in the 1950s and by the FDA in 1995. Today it is one of the most widely used antidiabetic drugs in the world.

The interest in longevity came from an unexpected observation. Several epidemiological studies found that people with diabetes treated with metformin had lower all-cause mortality than people without diabetes. It was as if the medicated patient outlived the healthy reference group. This set the scientific community alight: could metformin do something beyond blood sugar control?

In longevity medicine, carbohydrate metabolism — how we process glucose — is treated as a central piece of cardiometabolic prevention. If metformin modulates that metabolism, there is biological logic in exploring its geroprotective potential; what is still missing is proof that this potential improves healthspan outcomes in healthy adults.

How metformin works at the molecular level

Metformin does not have a single mechanism of action. It is described as a "dirty" drug (in a biochemical sense): it acts on multiple cellular targets simultaneously. Here are the main ones:

1. AMPK activation

AMPK (AMP-activated protein kinase) is the cell's "energy sensor." When ATP levels drop (the cell has less energy), AMPK activates and triggers conservation and recycling processes. Metformin inhibits Complex I of the mitochondrial electron transport chain, reducing ATP production and indirectly activating AMPK.

AMPK activation has an effect compared to caloric restriction: it inhibits mTOR, stimulates autophagy (cellular cleanup), and improves insulin sensitivity. In fact, many of the metabolic benefits of intermittent fasting come from activating this pathway. You can read more about this in our article on intermittent fasting and autophagy.

2. mTOR inhibition

mTOR (mechanistic target of rapamycin) is a pathway that integrates nutrients, energy and growth signals. In aging models, persistently high mTORC1 signalling is associated with lower autophagy and stronger cellular growth signalling. Metformin, through AMPK and other pathways, can partially inhibit mTORC1; that is mechanistically interesting, but it does not make it a proven longevity intervention for healthy adults.

This mechanism shares similarities with rapamycin and sirtuins, other pharmacological targets active in the longevity field.

3. Reduced inflammation and DNA damage

In type 2 diabetes and experimental models, metformin has been associated with lower C-reactive protein and modulation of pathways such as NF-κB, mitochondrial ROS and DNA damage. These effects connect to inflammaging, the chronic low-grade inflammation that accompanies aging and is one of the 12 hallmarks of aging. The caution: improving an inflammatory marker in a metabolic context does not prove clinical rejuvenation in healthy people.

4. Glucose metabolism effects

Metformin reduces hepatic glucose production (gluconeogenesis) and improves insulin sensitivity in muscle and liver. This means the body needs less insulin to process carbohydrates. Less circulating insulin is associated with reduced activation of growth pathways (like IGF-1) that accelerate cellular aging.

Mechanism	Cellular effect	Longevity relevance
AMPK activation	Mimics caloric restriction: energy conservation, autophagy	Strong evidence in animal models
mTORC1 inhibition	Dampens excessive cell growth	Same mechanism as rapamycin
Inflammation reduction	Lowers CRP, NF-κB, pro-inflammatory cytokines	Connected to inflammaging
Insulin sensitivity improvement	Less insulin, less IGF-1	Fewer cellular aging signals
Mitochondrial Complex I inhibition	Less ROS, less oxidative damage	DNA and mitochondrial protection

Current scientific evidence: what is proven and what is not

This is where we need to keep our feet on the ground. The evidence on metformin and longevity has layers, and not all carry the same weight.

Observational data: promising but biased

The study that started it all was Bannister et al. (2014), which analyzed over 78,000 diabetic patients treated with metformin monotherapy and found they had lower all-cause mortality than non-diabetic controls. A striking finding.

The problem: the metformin group consisted of healthier diabetics (those not requiring additional drugs), while non-diabetic controls may have included people with undiagnosed conditions. Also, the benefit disappeared in those over 60. A subsequent meta-analysis by Campbell et al. (2017) confirmed the trend but with the same methodological limitations.

In 2022, a Danish study (Keys et al.) failed to replicate Bannister's results: metformin users showed higher mortality than non-diabetics. And in 2025, the review "Emerging uncertainty on the anti-aging potential of metformin" pointed out that selection bias (comparing diabetics with "never-diabetics" who are often cardiovascular patients) artificially inflates control-group mortality.

Observational verdict: there is a biologically plausible signal, but the data does not allow us to conclude that metformin extends life in healthy people.

Clinical trials in humans: disappointing results

Several controlled trials have evaluated metformin in non-diabetic people, focusing on aging biomarkers and physical function:

• MILES Study: the Kulkarni et al. study was small (n=14), crossover and 6 weeks long in older adults with impaired glucose tolerance. It observed transcriptomic and biomarker changes in muscle and adipose tissue, but did not measure long-term clinical healthspan outcomes.
• MASTERS Trial (2019): metformin reduced muscle mass gains after a resistance training program in older adults. A relevant adverse effect, given that sarcopenia is a mortality risk factor.
• MET-PREVENT Trial (2025): published in The Lancet Healthy Longevity, this randomized trial included 72 older adults (mean age: 80 years) with probable sarcopenia and pre-frailty or frailty. They took 500 mg of metformin three times daily for 4 months. Four-meter walking speed did not improve versus placebo (adjusted difference: 0.001 m/s; p=0.96), and tolerability was worse, with more adverse events and hospital admissions.

Clinical verdict: metformin modifies molecular pathways related to aging, but this does not translate (yet) into measurable functional improvements in healthy people.

The macaque study (2024): the data point that revived the debate

In September 2024, a Chinese team published in Cell a 40-month study with cynomolgus monkeys (Yang et al., PMID: 39270656). They administered metformin at 20 mg/kg/day and evaluated 68 biological parameters. The results were striking:

• A reduction of ~6 years in biological brain age (based on DNA methylation clocks).
• Preserved cortical thickness, especially in the frontal lobe.
• Improved short-term memory and cognitive flexibility scores.
• Reduced inflammatory markers and cellular aging markers across multiple tissues.

However, the study has important limitations: the monkeys were obese and possibly diabetic (no baseline glucose data was published), there was no pre-study health data, only males were studied, and the epigenetic clock was validated on a small sample. It is an interesting preclinical result, not proof that a healthy person should take metformin.

Preclinical verdict: the primate study is the most solid to date in animal models close to humans, but it does not demonstrate efficacy in healthy people. It is a reason to keep researching, not to self-medicate.

The TAME trial: the definitive test (pending)

The TAME (Targeting Aging with Metformin) trial is a clinical study designed by Nir Barzilai at the Albert Einstein College of Medicine. AFAR's official resource describes it as a six-year series of trials across 14 sites, with Wake Forest University School of Medicine as the coordinating center and more than 3,000 adults aged 65-79. The goal is to test whether metformin delays the development or progression of age-related diseases: cardiovascular disease, cancer, dementia, and mortality.

The important nuance: as of 2026, no efficacy results have been published. AFAR still presents TAME as a prepared design that needs funding for full launch. If completed with positive results, it would be the first trial to treat aging as a medical indication, not just a risk factor. Until then, any claim that TAME has already proven metformin slows aging is ahead of the data.

Potential longevity benefits by system

Claim	Evidence level	Prudent 2026 read
Diabetes prevention in prediabetes	Established in trials	DPP showed lower diabetes incidence, stronger with lifestyle than metformin.
Lower long-term multimorbidity	New DPPOS/JAMA data	Lifestyle reduced risk; metformin was not significantly different from placebo.
Delayed aging in healthy adults	Not proven	TAME has no published efficacy results and direct human evidence is still pending.
Better muscle, strength or frailty	Not supported	MASTERS and MET-PREVENT argue for caution, especially when the goal is preserving muscle.
Neuroprotection or inflammation	Preclinical/observational	Biologically plausible, but not enough for anti-aging prescription in healthy adults.

Metabolism and glucose

Metformin's metabolic effect is well established: it improves glucose control, reduces HbA1c and decreases hepatic glucose production. In people with insulin resistance or prediabetes it can be useful, but it does not outperform a strong lifestyle program. The NIDDK Diabetes Prevention Program showed that lifestyle intervention reduced type 2 diabetes incidence by 58% and metformin by 31% versus placebo. The DPPOS follow-up published in JAMA in 2026 added another nuance: for 21-year multimorbidity, lifestyle was associated with lower risk; metformin was not significantly different from placebo.

Long-term follow-up also helps put it in context. In the 15-year DPPOS analysis, diabetes incidence remained lower versus placebo: 27% lower with intensive lifestyle intervention and 18% lower with metformin. This supports two points at once: metformin can be useful prevention in high-risk metabolic profiles, and structured lifestyle remains the comparator no serious longevity discussion can skip.

For people with normal metabolism, the additional benefit is uncertain. Metabolic biomarkers like HbA1c, HOMA-IR, and fasting glucose should guide the decision, not speculation.

Brain and cognition

The macaque study suggests neuroprotection, and some observational human data has explored lower cognitive-decline risk in metformin users. But the evidence is inconsistent: other studies find no effect, and in older adults with hyperglycemia metformin use has been associated with B-vitamin deficiency and poorer cognitive performance. The prudent reading is that brain health does not justify self-medication; it does justify monitoring B12 and separating promising mechanisms from proven outcomes.

The TAME trial will include cognitive assessments, which could clarify this question in the coming years.

Inflammation and cellular aging

Metformin may reduce part of low-grade inflammation in metabolic contexts such as type 2 diabetes, especially CRP in some meta-analyses. That connects it with inflammaging, but it does not make it a universal anti-inflammatory treatment or a clinical senolytic. For a full-spectrum anti-inflammatory strategy, anti-inflammatory nutrition, muscle, sleep and visceral-fat reduction remain the foundation.

Side effects and who should NOT take metformin

Metformin has a reasonable safety profile, but it is not harmless. Here are the most relevant adverse effects:

Adverse effect	Frequency	Notes
GI issues (nausea, diarrhea)	20-30% of users	Usually improves over time; take with food
Vitamin B12 deficiency	6-10% with long-term use	Requires monitoring; can cause neuropathy
Reduced muscle gain from exercise	Documented in MASTERS (2019)	Interferes with resistance training adaptations
Lactic acidosis (rare)	<0.1% but potentially fatal	Real risk in severe kidney failure
Drug interactions	Variable	Review with doctor; affects iodinated contrast, alcohol

Do NOT take metformin without medical supervision if you have:

• Moderate-to-severe kidney failure (eGFR < 30 mL/min)
• Advanced liver disease
• History of lactic acidosis
• Pregnancy or breastfeeding
• Excessive alcohol consumption
• Before surgery or iodinated contrast imaging

Additionally, if your exercise routine includes regular strength training — and it should, if you care about longevity — evidence from the MASTERS and MET-PREVENT trials suggests metformin may reduce your muscle mass gains or fail to improve physical function when frailty is already present. This matters: sarcopenia is one of the strongest predictors of mortality in older adults.

What to measure before considering metformin

Before discussing metformin for prevention, it helps to separate three scenarios: metabolic treatment, prevention in a high-risk profile, and anti-aging use without a medical indication. That distinction keeps a useful drug from becoming a trend.

Clinical question	Useful markers	How it changes the decision
Is insulin resistance present?	HbA1c, glucose, fasting insulin, HOMA-IR, triglycerides, waist	If there is a real abnormality, metformin can enter a reasonable medical discussion.
Is muscle reserve at risk?	Grip strength, chair-stand test, body composition, protein intake, training	If muscle is the bottleneck, prioritize strength, protein and follow-up before medication.
Is it safe for this patient?	eGFR, liver function, B12, alcohol intake, medications, upcoming surgery or contrast imaging	It may need to be avoided, paused, dose-adjusted or monitored more closely.

This connects with our guide to sarcopenia: if an intervention worsens or fails to improve muscle reserve, it is not a complete longevity strategy even if one biomarker improves.

Metformin in personalized longevity programs

In the context of current longevity medicine, metformin is considered a potential tool within a broader approach. It is not a shortcut, and no responsible physician prescribes it for longevity without first evaluating the patient's complete metabolic profile.

A personalized approach includes:

1. Complete metabolic assessment: HbA1c, fasting insulin, HOMA-IR, postprandial glucose, lipid profile, body composition.
2. Individual risk evaluation: family history, genetics (pharmacogenetics to predict drug response), current lifestyle.
3. Risk-benefit balance: if you already have insulin resistance or prediabetes, the profile is favorable. If your metabolism is optimal and you strength train regularly, the benefit is questionable and the risk of exercise interference is real.
4. Continuous monitoring: B12, kidney function, HbA1c, and body composition every 6-12 months.

Metformin, if used, should first sit on top of the interventions with the strongest clinical evidence for healthspan: evidence-based nutrition, strength training, adequate sleep and chronic inflammation reduction. Interventions such as NAD+ can be considered as measured adjuncts in selected cases, not as substitutes or equivalent-evidence foundations.

The Progevita perspective: drugs, lifestyle, and integrated diagnostics

At Progevita we approach longevity from an integrative model. This means we do not dismiss pharmacological interventions when evidence supports them, but we also do not use them as shortcuts.

Our approach combines diagnostics, medical conversation and lifestyle planning before considering drugs. Metformin may have a place when the metabolic profile justifies it, but never as a substitute for fundamentals: exercise, nutrition, sleep and stress management.

If you want to know whether your metabolic profile justifies a medical conversation, start with an individual assessment, not a generic longevity prescription.

Frequently asked questions

Does metformin slow aging?

There is observational and preclinical evidence suggesting a possible geroprotective effect, but no clinical trials demonstrate this in healthy people. TAME is designed to answer that question if completed. What is established is metformin's role in glucose control and diabetes prevention in selected high-risk profiles, not that it extends healthspan by itself.

What is the TAME trial status in 2026?

As of 2026, TAME has no published efficacy results proving that metformin slows aging or extends healthspan in humans. It remains an important proposed trial design because it would test age-related disease delay across cardiovascular disease, cancer, dementia and mortality, but clinical decisions today should still depend on metabolic indication, safety checks and medical supervision.

Can I take metformin to live longer if I do not have diabetes?

There is not enough evidence to recommend it. Observational studies have significant biases, and clinical trials in non-diabetic people have produced mixed or negative results. Additionally, metformin may interfere with strength training adaptations — an intervention with much stronger longevity evidence.

What is the metformin dosage for longevity?

There is no validated metformin dose for longevity in healthy adults. Clinical doses for diabetes or prediabetes are adjusted by tolerance, kidney function and physician judgment, but that is not the same as an anti-aging protocol. Before asking for dosage, you should know your HbA1c, fasting insulin, eGFR, B12, body composition, training goal and medical reason for considering it.

How much does metformin cost?

It is one of the cheapest drugs on the market. In Spain, the price with a prescription is between 3 and 10 euros per month. In the US, generic metformin costs between $4 and $15 per month. This is part of its appeal as a potential longevity intervention: if it worked, it would be accessible to almost everyone.

What are the most common side effects of metformin?

The most frequent are gastrointestinal: nausea, diarrhea, abdominal pain, and loss of appetite. They occur in 20-30% of users and typically improve after the first few weeks. Long-term use can also cause vitamin B12 deficiency (6-10% of patients), so monitoring levels is advisable.

How does metformin compare to rapamycin for longevity?

Rapamycin inhibits mTOR more directly and potently than metformin, and has more consistent results in animal models. However, its immunosuppressive effects are more pronounced, and its long-term safety profile in healthy people is less well known. Both drugs share activation of caloric-restriction-related pathways, but rapamycin is more advanced as a geroprotective candidate in the scientific literature.

Is metformin useful for weight loss?

It produces modest weight loss (about 2-3 kg on average after one year of use), but it is not a weight-loss drug. The effect is partially independent of glycemic improvement. If the goal is body composition, strength training and personalized nutrition are far more effective.

Conclusion

Metformin is a drug with an extensive clinical history, a reasonable safety profile, and real biological plausibility as a longevity tool. The molecular mechanisms are well described — AMPK, mTOR, inflammation, glucose metabolism — and converge on the same processes that the science of aging identifies as key drivers.

But evidence in healthy humans is limited. Observational data has biases. Clinical trials have produced mixed results. And the negative effect on muscle gain with exercise is a real drawback for active people.

If you have insulin resistance or prediabetes, metformin may be a reasonable option inside a medical conversation. But DPPOS is an uncomfortable reminder for the anti-aging narrative: for long-term multimorbidity, lifestyle won where metformin was not significantly different from placebo. If your metabolism works well and your priority is longevity, the smartest move is to invest in what has stronger clinical translation: strength training, nutrition, sleep, aerobic capacity and a diagnostic workup that tells you where you stand.

If you want to know where you stand, start here.

References

1. Bannister CA et al. "Can people with type 2 diabetes live longer than those without?" Diabetes Obes Metab. 2014. PMID: 25041462.
2. Yang Y et al. "Metformin decelerates aging clock in male monkeys." Cell. 2024. PMID: 39270656.
3. Barzilai N et al. "Metformin as a Tool to Target Aging." Cell Metab. 2016. PMID: 27304507.
4. American Federation for Aging Research. "TAME - Targeting Aging with Metformin." Official trial resource. Accessed June 2026.
5. Kulkarni AS et al. "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults." Aging Cell. 2018. PMID: 29383869.
6. Konopka AR et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 2019. PMID: 30548390.
7. Walton RG et al. "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults." Aging Cell. 2019. PMID: 31557380.
8. Witham MD et al. "Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT)." Lancet Healthy Longev. 2025;6(3):100695. PMID: 40147475. DOI: 10.1016/j.lanhl.2025.100695.
9. Diabetes Prevention Program, NIDDK. Official DPP and DPPOS overview. Accessed June 2026.
10. Diabetes Prevention Program Research Group. "Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up." Lancet Diabetes Endocrinol. 2015. PMID: 26377054.
11. Salive ME et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. DOI: 10.1001/jama.2026.8492.
12. National Institutes of Health. "For adults with prediabetes, lifestyle intervention lowered risk of developing multiple chronic conditions." News release, June 15, 2026.
13. Campbell JM et al. "Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control." Ageing Research Reviews. 2017. PMID: 28802803. DOI: 10.1016/j.arr.2017.08.003.
14. Keys MT et al. "Metformin's effect on mortality and the actual causes of death in patients with type 2 diabetes: a Danish population-based cohort study." International Journal of Epidemiology. 2022. PMID: 36287641. DOI: 10.1093/ije/dyac200.
15. Zhou G et al. "Role of AMP-activated protein kinase in mechanism of metformin action." J Clin Invest. 2001. PMID: 11602624. DOI: 10.1172/JCI13505.
16. Moore EM et al. "Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults." J Clin Endocrinol Metab. 2019;104(10):4837-4847.
17. Suvarna R et al. "Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Ann Pharmacother. 2021. PMID: 33412927.
18. "Emerging uncertainty on the anti-aging potential of metformin." Ageing Research Reviews. 2025. DOI: 10.1016/j.arr.2025.102817.
19. Zhang T et al. "The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications." Molecules. 2025;30(4):816. DOI: 10.3390/molecules30040816.
20. DailyMed / NIH. Metformin hydrochloride tablets: prescribing information on renal impairment, iodinated contrast, surgery and vitamin B12. Accessed June 2026.
21. American Diabetes Association. "Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026." Diabetes Care. 2026.
22. Roberts MN et al. "Geroprotector drugs and exercise: friends or foes on healthy longevity?" BMC Biology. 2023;21:297. DOI: 10.1186/s12915-023-01779-9.